SOURCE: Goldman Small Cap Research, Inc.
BALTIMORE, MD--(Marketwired - Oct 31, 2013) - In a newly released article, Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, notes that savvy traders and followers of Nuvilex, Inc. (OTCQB: NVLX) can sense that a return to much higher levels is brewing. For starters, the Company's shares have reached a key pivot point at current levels and have strong support at the $0.112/$0.113 mark. As a result, even the slightest catalytic event could take the stock through its near term resistance point of $0.122 and back to the $0.15 range where it based earlier this summer.
Close followers of the stock are likely aware that management provided shareholders with a glimpse of major events ahead which would certainly qualify as a catalytic event to propel the stock higher. A few months ago, Nuvilex management announced that it anticipated closing the acquisition of rights to a live-cell-based encapsulation therapy to treat diabetes in October. This delivery system and mechanism of action is similar to the current live-cell encapsulation technology the company owns to treat pancreatic cancer as well as all other solid tumors.
Well, the month is just about over so could this be the catalytic event the stock needs?
With estimated annual sales of $22 billion for diabetes drugs in the U.S., this deal would be a game-changer. Moreover, from the clinical standpoint, it is the logical play. Clinicians and physicians have long known about the undefined correlation between the litany of health problems associated with diabetes and the link to pancreatic cancer, which is one of the reasons why the Nuvilex deal makes so much sense.
Several research studies have found that about 80% of patients who have pancreatic cancer also have glucose intolerance issues or diabetes. Another study found that people diagnosed with diabetes after age 50 are eight times more likely to develop pancreatic cancer compared with the general population.
Clearly, Nuvilex plans to take advantage of the soon-to-be acquired early-stage diabetes treatment rights and research combined with its advanced pancreatic cancer trials data to leverage the platform live-cell encapsulation technology to treat both diseases. With the treatment therapy for both diseases under the same roof, it is likely that Nuvilex's shares enjoy an extended run-up rather than just a swift move back to a former trading level.
This press release contains excerpts of our most recently published article on Nuvilex. To view all of our sponsored Nuvilex reports, updates, articles, disclosures and disclaimers, or to download the article in its entirety, please visit www.goldmanresearch.com.
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and micro cap stock research reports, articles, daily stock market blogs, and popular investment newsletters. Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.
A Goldman Small Cap Research report, update, newsletter, or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.
About Nuvilex, Inc. (OTCQB: NVLX): Nuvilex, Inc. is an international biotechnology firm focused on developing and preparing to commercialize treatments for cancer, diabetes and other diseases based on the live, therapeutically valuable, encapsulated cells platform. The Company is leveraging its cancer biology and clinical oncology research experience and expertise, particularly for use in oncology treatments, in addition to initiating oncology applications of medical marijuana. For more information visit: www.nuvilex.com.